Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medico Remedies Limited reported strong annual performance for FY2026 ending March 31, 2026. Revenue from operations grew 36.85% to Rs. 20,637.73 lakhs from Rs. 15,094.06 lakhs in FY2025. Net profit after tax increased 30.04% to Rs. 1,312.52 lakhs from Rs. 1,009.32 lakhs year-over-year. The company manufactures pharmaceutical formulations and exports form a significant portion of sales. The statutory auditor Shah Shroff & Associates issued an unmodified opinion on the financial statements, indicating no concerns. Q4 standalone revenue was Rs. 5,680.77 lakhs with net profit of Rs. 585.66 lakhs. The auditor was changed from V J Shah & Co (previous auditor) to Shah Shroff & Associates for this period.
Positive signal for shareholders as the company delivered robust revenue and profit growth exceeding 25%. Clean audit opinion with no going concern issues provides assurance on financial health, though EBITDA margin showed slight compression.